Thermogenic and metabolic antiobesity drugs: rationale and opportunities

J. C. Clapham\(^1\) and J. R. S. Arch\(^2\)

\(^1\)Department of Molecular Pharmacology, AstraZeneca R & D Mölndal, Mölndal, Sweden
\(^2\)Clore Laboratory, University of Buckingham, Buckingham, UK

Antiobesity drugs that target peripheral metabolism may avoid some of the problems that have been encountered with centrally acting anorectic drugs. Moreover, if they cause weight loss by increasing fat oxidation, they not only address a cause of obesity but also should promote loss of fat rather than lean tissue and improve insulin sensitivity. Weight loss may be slow but more sustained than with anorectic drugs, and thermogenesis may be insufficient to cause any discomfort. Some thermogenic approaches are the activation of adrenergic, thyroid hormone or growth hormone receptors and the inhibition of glucocorticoid receptors; the modulation of transcription factors [e.g. peroxisome proliferator-activated receptor \(\delta\) (PPAR\(\delta\)) activators] or enzymes [e.g. glutamine fructose-6-phosphate amidotransferase (GFAT) inhibitors] that promote mitochondrial biogenesis, and the modulation of transcription factors (PPAR \(\alpha\) activators) or enzymes (AMP-activated protein kinase) that promote fatty acid oxidation. More surprisingly, studies on genetically modified animals and with enzyme inhibitors suggest that inhibitors of fatty acid synthesis [e.g. ATP citrate lyase, fatty acid synthase, acetyl-CoA carboxylase (ACC), fatty acid interconversion (stearoyl-CoA desaturase (SCD)) and triglyceride synthesis (e.g. acyl-CoA : diacylglycerol acyltransferase)] may all be thermogenic. Some targets have been validated only by deleting genes in the whole animal. In these cases, it is possible that deletion of the protein in the brain is responsible for the effect on adiposity, and therefore a centrally penetrant drug would be required. Moreover, whilst a genetically modified mouse may display resistance to obesity in response to a high fat diet, it requires a tool compound to demonstrate that a drug might actually cause weight loss. Even then, it is possible that differences between rodents and humans, such as the greater thermogenic capacity of rodents, may give a misleading impression of the potential of a drug.

Keywords: hormone mimetics, hypothalamus, lipid metabolism, mitochondrial biogenesis, obesity drugs, thermogenesis

Received 1 April 2005; returned for revision 1 March 2006; revised version accepted 9 March 2006

Introduction

It is well recognized that the onslaught of obesity is a serious problem for affluent societies. Many reviews over recent years have documented the pandemic, its possible causes and actual and potential treatments, including pharmacotherapy. There are, however, only two widely approved drugs for the treatment of obesity: sibutramine, which acts centrally to inhibit serotonin and noradrenaline reuptake, and orlistat, which acts in the gut to inhibit fat digestion. Rimonabant, which is an inverse agonist of the CB\(_1\) cannabinoid receptor, may be approved in 2006, having produced good weight loss in phase III clinical trials [1]. It acts centrally to reduce the motivation to eat, especially the consumption of palatable food, and may also act centrally to activate...
thermogenesis [2,3]. Whether its actions at the CB-1R in adipose tissue [4,5] contribute significantly to its effects on energy balance is unclear. A number of other centrally acting drugs (e.g. fenfluramine and phentermine) have been withdrawn due to either their toxicity or their abuse potential, or their use is heavily regulated. Others, such as ephedrine and its close analogue phenylpropanolamine, may be obtained over the counter in some countries, but adverse effects are a serious concern.

Concern about the safety of centrally acting drugs is one reason why pharmaceutical companies are seeking alternative approaches for the treatment of obesity. Perhaps the fact that orlistat is not even absorbed from the gut is one factor that weighed in favour of a good benefit-to-risk ratio, despite its relatively low antiobesity efficacy [6,7]. Fortunately, studies on genetically modified rodents are revealing many peripheral (or apparently peripheral – see Hypothalamic Targets and Their Implications for Drug Discovery) targets for antiobesity drugs [8]. Broadly speaking, these alternative approaches might be termed metabolic, meaning that the drug regulates fat or carbohydrate metabolism by a means other than altering the level of a neurotransmitter or the activation of a neuronal receptor, or thermogenic, meaning that the drug increases energy expenditure. Clearly, many drugs might be both metabolic and thermogenic, but it is possible for metabolic antiobesity drugs to reduce energy intake and for drugs that target neuronal receptors to be thermogenic. It should also be understood that the initial site of action of both metabolic and thermogenic drugs can be in the brain. Metabolic and thermogenic drugs should preferably act in the periphery, however, if they are to avoid exceptional scrutiny by regulatory authorities.

**Rationale for Thermogenic Drugs**

**Aetiology of Obesity**

There are aetiological arguments for thermogenic drugs being a rational approach to the treatment of obesity. The first of these is that reduced energy expenditure due to our modern lifestyles shares, with increased energy intake, responsibility for the modern obesity epidemic. Second, those who are more susceptible to this ‘obesogenic’ environment have a lower daily energy expenditure [9] and seem to expend less energy on everyday activities that involve muscle movement (‘non-exercise activity thermogenesis’) [10,11]. Whether drugs other than CNS stimulants can increase muscular activity is questionable, but a recent study found that a low resting metabolic rate is also predictive of susceptibility to obesity [12]. Resting metabolic rate may be more amenable to pharmacotherapy, but its association with obesity is more controversial [13]. Once they have become obese, humans actually tend to have an elevated resting metabolic rate and so must consume more energy than lean people to maintain their obesity. It does not necessarily follow that they became obese by overeating, however. There are examples of genetically modified obese mice in which hyperphagia develops after obesity [14]. Moreover, some, though not all, studies suggest that slimmed down (‘post-obese’) subjects have a reduced metabolic rate [15].

A third argument, specifically for thermogenic drugs that stimulate fat oxidation, is that fat oxidation is defective in people who are susceptible to obesity, both when they are obese and after they have slimmed [16,17]. The significance of this finding is that fat storage is poorly regulated in all subjects (hence obesity is a problem) compared with carbohydrate (glycogen) and protein storage, which are under much tighter control [18]. Those who resist obesity display increased fat oxidation in response to increased dietary fat, whereas obese subjects seem unable to increase fat oxidation, as assessed by the measurement of respiratory quotient. In other words, those who are susceptible to obesity have even less control of the size of their fat stores than others, because they cannot burn off excess fat.

Irrespective of whether obese subjects have a generally low energy expenditure or a defect specifically in fat oxidation, the phenomenon is likely to reside partly in skeletal muscle, which accounts for 20% of basal metabolic rate [19] and a greater proportion of daily energy expenditure. It is therefore not surprising that differences in respiratory quotient between lean and obese subjects are also seen in muscle biopsy samples [20]. These differences may reflect muscle fibre type. Human skeletal muscle is composed of slow (type I) fibres, which are predominantly oxidative and use fatty acids as their fuel, and fast (type II) twitch fibres. The latter can be predominantly glycolytic (type IIb) or mixed glycolytic and oxidative (type IIa). Increased type I fibre content is associated with a tendency for reduced adiposity and reduced type I fibre content with obesity. As with respiratory quotient, fibre type influences successful maintenance of weight loss. For example, following bariatric surgery weight loss was directly proportional to the proportion of type I oxidative fibres in the rectus abdominus [21].

**Therapeutic Benefits**

Further arguments for thermogenic drugs are that those that promote fat oxidation – this includes those that in
some way mimic the sympathetic nervous system – cause selective loss of fat and improvements in insulin sensitivity beyond those expected from the reduction in body weight. Thus a variety of evidence demonstrates that sympathomimetic agents, such as β2-adrenoceptor agonists, depend on fat oxidation for thermogenesis, and, provided food intake does not decrease, all the weight loss that results is due to fat loss [22,23]. Weight loss in response to moderately reduced energy intake, by contrast, typically includes about 15–25% of fat-free mass, though this proportion can vary widely [24,25]. Insulin sensitivity may be improved, because the stimulation of fat oxidation causes rapid falls in lipid metabolites, such as diacylglycerol, that are known to inhibit insulin signalling [22,26]. By contrast, the triglyceride stores that cause adiposity are so large that it must take longer for increased fat oxidation to deplete them.

Thermogenic drugs that mimic the sympathetic nervous system or depend on the capacity for fat oxidation may not cause as much weight loss as anorectic drugs in the short term. Past and present anorectic drugs initially produce weight loss of about 0.23 kg per week [27,28]. If 15% of this weight loss is lean tissue, which consists of 75% water and contains 1 kcal per gram, and 85% is fat, which contains 9 kcal per gram, then the loss of energy per day is 256 kcal. This is roughly a 10% alteration in energy balance for an obese subject. The uncoupling agent dinitrophenol (see Miscellaneous Intracellular Targets) may have increased energy expenditure by much more than 10%, but most thermogenic drugs – at least those that in some way mimic the sympathetic nervous system or depend on the capacity for fat oxidation – are unlikely to have much more effect than anorectic drugs. Thus isoprenaline increases energy expenditure by at most 30% in humans [29], and a drug acting by a similar mechanism would do well to use a third of this capacity.

A disadvantage of selective fat loss, which adds to the possible problem of slow weight loss, is that for the same negative energy balance there is less effect on body weight: the historical value of 0.23 kg per week for anorectic drugs quoted above becomes 0.20 kg for a drug that has the same percentage effect on energy balance but causes only fat loss [22,23]. Nevertheless, if this weight loss was achieved in a 100-kg subject for just 6 months, the resultant weight loss of 5.2 kg would meet the FDA goal of 5% weight loss relative to placebo over a year or the EMEA goal of 10% weight loss, which includes weight loss achieved by lifestyle modification – typically another 5%. It would be more difficult to achieve regulatory goals if a sympathomimetic thermogenic drug (like exercise) increased the amount of lean tissue [22,23].

Satisfying regulatory authorities is different from satisfying patients, who would value much greater weight loss. Because exercise seems to be important in maintaining long-term weight loss [30], perhaps thermogenic drugs would be especially beneficial in those subjects who could achieve rapid initial weight loss by dieting or with the aid of an anorectic drug. Indeed, it is possible that weight loss in response to a thermogenic drug would last longer than the 6 months generally seen with anorectic drugs. In rodents at least, the effect of sympathomimetic agents increases in the early stages of treatment, provided animals are obese and can therefore provide fuel for thermogenesis [22]. Obese animals do not normally compensate by eating more, just as moderate exercise in obese humans does not in the short-term increase food intake [31]. By contrast, various centrally acting agents, such as sibutramine, phentermine and bupropion, reduce food intake for a few days at most in rodents, and it is thermogenesis that accounts for their antiobesity activity over a period of weeks [32–34]. This does not mean that anorectic agents are no longer influencing food intake: body weight stays below the control level, and if the anorectic agent is withdrawn, then there is a rebound hyperphagia. It seems therefore that the effect of the anorectic agent meets opposition from counter-regulatory forces. Where such forces (e.g. a low plasma leptin level) are due to loss of fat, they will oppose both thermogenic and anorectic agents [35,36]. However, signals that indicate that the gut is empty or that an individual is hedonically or socially deprived will only oppose anorectic drugs.

There is a common concern that taking a thermogenic drug will make people feel permanently hot, as happened with dinitrophenol (see Miscellaneous Intracellular Targets). It is important to note, however, that if a thermogenic drug increases energy expenditure by 10 or even 20%, then it is unlikely to produce discomfort. In one study, ‘sitting and fidgeting’ increased energy expenditure by 54%, and walking at only 1.6 km/h increased it by 154% compared with lying down [10]. Of course, this means that those who fidget or walk for much of the day are unlikely to be obese.

Biochemistry and Endocrinology of Thermogenesis

How does the energy generated by thermogenic drugs end up as heat? The great majority of the chemical energy in the macronutrients is funnelled through NADH or (in the mitochondrion) FADH. Most of the
energy carried by these coenzymes is then used to produce ATP, mainly by oxidative phosphorylation in the mitochondrion. A small amount of energy is funnelled through NADPH, which is used in various anabolic reactions. Together with NADH, NADPH can also be consumed by non-mitochondrial oxidases that do not conserve chemical energy by producing ATP (figure 1).

Thermogenic agents must increase either the utilization of ATP or the oxidation of the reduced coenzymes by pathways that are not coupled to ATP synthesis, for example by uncoupling oxidative phosphorylation. Excluding growth, in which some of the energy in ATP is retained, ATP utilization may involve ion transport, simple substrate cycles or more complex cycles. An example of a simple substrate cycle is the phosphorylation of fructose-6-phosphate to fructose-1,6-bisphosphate and hydrolysis of the bisphosphate back to the monophosphate. More complex cycles include triglyceride and protein turnover, and the Cori cycle, in which glucose and lactate are transferred between muscle and liver.

In the resting state, about 90% of oxygen consumption takes place in the mitochondrion, and 80% of this is coupled to ATP synthesis. Perhaps 30% of the ATP is used for Na\(^+\)/K\(^+\) and Ca\(^{2+}\) pumps, 30% for protein synthesis and 20% for gluconeogenesis, ureagenesis and in turning over carbohydrate and lipid stores [19].

Resting metabolic rate in humans can be increased by about 30% by the sympathetic nervous system [29] and by about 15% by growth hormone [37]. Thyroid hormones can increase metabolic rate by about 15%, and hypothyroidism reduces it by 30% [38]. Glucocorticoids suppress energy expenditure in rodents [39], but in humans cortisol and methylprednisolone have been shown to increase resting energy expenditure by up to 15% and about 7%, respectively [40,41].

Uncoupling of oxidative phosphorylation in brown adipose tissue is a major thermogenic mechanism in response to sympathetic activation in rodents, but in humans, the stimulation of ATP utilization is more important. Thyroid hormones sensitize tissues to the sympathetic nervous system and also have a number of independent effects [42], including the stimulation of protein turnover. The net effect on protein turnover involves more loss of lean tissue than does a low energy diet [23]. Growth hormone, by contrast, stimulates protein synthesis and conserves protein. It also promotes lipolysis and fatty acid oxidation [43]. Glucocorticoids suppress sympathetic activity and the responsiveness of brown adipose tissue to sympathetic activity in rodents [44]. In humans, however, the stimulation of protein turnover and catabolism may have the predominant influence on energy expenditure.

**Hormone Mimetics and Antagonists**

Various approaches have been employed to mimic or (in the case of glucocorticoids) block these hormone systems to develop thermogenic drugs (figure 2).

**Thyroid Hormones**

Thyroid hormones were used to treat obesity in the 1890s. Weight loss was, however, accompanied by increased protein catabolism and cardiac stimulation. Selective stimulants of the thyroid hormone receptor-\(\beta\) may have less effect on the heart than thyroid hormones [45]. One such compound, GC-1, reduced body weight in cynomolgus monkeys by 4% over 7 days without any evidence of muscle wasting. There was also, however, no evidence of muscle wasting over 7 days in response to triiodothyronine at a dose level that caused similar weight loss [46]. Other potentially deleterious effects, such as bone loss, fatigue and CNS effects, were not evaluated [47].

---

**Fig. 1** Production and utilization of reduced adenine dinucleotides and ATP. Hormones and drugs that increase energy expenditure must increase either the utilization of ATP or the oxidation of reduced coenzymes by pathways that are not coupled to ATP synthesis.
Sympathetic Nervous System

Most anorectic drugs also increase energy expenditure [48]. Thermogenesis may, like the anorectic effect, be initiated centrally, or it may be a direct peripheral action. For example, ephedrine acts centrally to raise sympathetic activity and peripherally to stimulate the release of noradrenaline from nerve endings, as well as to directly activate β-adrenoceptors in non-neuronal tissues. Sibutramine, by contrast, seems only to increase sympathetic activity, though whether this contributes to weight loss in humans is unclear [49].

Unfortunately, sibutramine not only increases sympathetic outflow to tissues that are important for thermogenesis but also raises heart rate and blood pressure. Ephedrine has the same problems. Indeed, it is advisable to be cautious when any novel, centrally acting agent raises energy expenditure, because this may be due to a generalized increase in sympathetic activity. There is some evidence that it might be possible to activate the sympathetic nervous system selectively with a centrally acting agent [50], but this has not been demonstrated with a drug candidate.

β3-Adrenoceptor agonists stimulate fat oxidation in rodents without producing the cardiovascular side effects associated with β1- and β2-adrenoceptor stimulation. Unfortunately, the human β3-adrenoceptor differs from the rodent receptor, and those compounds that selectively activate the human receptor have mostly displayed poor oral bioavailability or have been rapidly excreted. Moreover, β3-adrenoceptor agonists have less effect on energy expenditure in humans than in rodents. Weight loss following 28 days’ treatment with the β3-adrenoceptor agonist L-796568 was correlated with the blood level of the compound [51], but the results were not deemed sufficiently exciting to attempt to improve bioavailability further or conduct a longer trial. A longer (12 week) study with ephedrine produced significant weight loss [52].

Lipid-mobilizing factor/Zn–α2–glycoprotein is produced by tumours and adipose tissue [53] and has been claimed to stimulate β3-adrenoceptors [54,55], though perhaps it promotes responses mediated by any Gαs-coupled receptor. Its effects on energy balance and body composition are similar to those of β3-adrenoceptor agonists, raising the possibility that, as an injectable drug, it could be successful where β3-adrenoceptor agonists have so far failed.

Growth Hormone

AOD 9401 is a synthetic analogue of growth hormone in phase II clinical trials that is reported not to affect blood glucose or growth [56]. Weight loss of 2 kg over 12 weeks relative to placebo was achieved with a dose of 1 mg per day in a phase Ia study, but higher doses were less effective [57]. The obvious suggestion that this was because higher doses cause a gain in lean body mass that equalled the loss in fat mass seems to have been ruled out. A further study is being conducted at doses of 1 mg and below.
Leptin

Leptin is released primarily from adipocytes and signals to the brain whether fat stores are adequate. In rodents, leptin not only decreases food intake but also increases energy expenditure, the latter effect being mainly due to increased sympathetic outflow. Presumably, leptin might have similar effects in humans if they are thin enough to have low leptin levels, but marked effects of leptin on energy balance have been demonstrated only in rare obese individuals that totally lack leptin. Leptin and modified leptins have not proved of benefit in most obese subjects [58]. Low molecular weight leptin mimetics that bypass the transporter that takes leptin into the brain may have greater potential [59].

Axokine is a modified version of ciliary neurotrophic factor, which shares some signalling mechanisms with leptin. It is therefore no surprise that Axokine increases energy expenditure and produces weight loss that is not all due to reduced food intake [60,61]. Because leptin raises energy expenditure by increasing sympathetic outflow, it is likely that Axokine acts similarly. Axokine performed well in phase II trials, but less well in phase III, possibly due to the generation of neutralizing antibodies.

Adiponectin

Adiponectin is a protein that is secreted by adipose tissue, especially by small adipocytes. It reduces weight gain and adipose tissue mass by stimulating fatty acid oxidation in muscle and liver. It seems to play an important role in the insulin sensitizing effects of thiazolidinedione antidiabetic drugs [62,63] (though these cause weight gain through other mechanisms). The discovery of two receptors for adiponectin provides possible new targets, though whether these receptors are amenable to small molecular weight activators remains to be seen [64].

Miscellaneous Intracellular Targets

Uncoupling Agents

Dinitrophenol, which uncouples the oxidation of NADH and FADH from ATP synthesis in the mitochondrion, was used as an antiobesity agent in the 1930s. Weight loss was as much as 3 kg per week but side effects included sweating and, more seriously, hypoxia at higher doses [16]. Perhaps lower doses of dinitrophenol or a similar uncoupling agent might retain adequate efficacy and also be safe.

In recent years, there has been greater interest in the uncoupling proteins (UCPs). The identification of at least five paralogs of the brown fat UCP-1 and their putative roles has been reviewed elsewhere [73]. UCP-1, -2 and -3 have been studied most. UCP-1 clearly plays a role in the regulation of energy expenditure and body weight in rodents but is less important in humans. UCP-2 and -3 can uncouple oxidative phosphorylation, but whether they are normally involved in the regulation of energy expenditure is questionable [73]. Irrespective of their normal roles, can any UCP be exploited as a target for antiobesity drugs? UCP-3 is of interest because of its predominant expression in skeletal muscle and because transgenic overexpression of UCP-3 in skeletal muscle produced mice with reduced adiposity, insulin, glucose...
and cholesterol levels, despite their eating more than their wild-type littermates [74]. Mitochondria from the transgenic mice were more uncoupled, but there is debate as to whether this is an artefact. There appears to be little current activity in the area of UCP activators, although a series of 2-(1-pyrazolyl) thiazole derivatives have been described by Tularik as increasing UCP-3 mRNA more than 10-fold in rat-derived L6 muscle cells [75].

**AMP-Activated Protein Kinase**

AMP-activated protein kinase (AMPK) is a multi-subunit enzyme that plays a key role in the regulation of energy provision within cells, initiating cascades that increase fat oxidation, decrease fat synthesis and enhance glucose uptake to maintain cellular energy stores [76]. AMPK appears to have a central role in enhancing glucose uptake to maintain cellular energy increase fat oxidation, decrease fat synthesis and energy provision within cells, initiating cascades that enhance glucose uptake to maintain cellular energy stores

AMPK is activated by various upstream kinases, including the LKB1 tumour suppressor protein kinase [87,88]. Searching for AMPK activators using a whole cell screen is difficult because any agent that raises the AMP : ATP ratio of the cell will cause the activation of AMPK, as has been found for example in the UCP-3 overexpressing mouse [89]. The activation of AMPK in the stearoyl-CoA desaturase-1 (SCD-1) knockout mouse (see Inhibition of Lipid Synthesis) might also be due to elevation of the cytosolic AMP concentration [90].

**Mitochondrial Biogenesis**

Various proteins might be targeted to promote mitochondrial biogenesis or the proportion of type 1 fibres in skeletal muscle. One of these is peroxisome proliferator-activated receptor γ (PPARγ) coactivator-1α (PGC-1α). This is a transcriptional activator that interacts with a number of nuclear hormone receptors. It is found mainly in type I rather than type II skeletal muscle fibres, and its expression is increased by cold and exercise, which increase mitochondrial biogenesis. Overexpression of PGC-1α in mouse C2C12 myotubes increased oxygen consumption and mitochondrial biogenesis, and overexpression of in type II fibres resulted in their conversion to a more type I-like phenotype [91].

PGC-1α itself may not be amenable to small molecular weight drugs because it has no natural small ligands. However, both PGC-1α and the related PGC-1β enhance the activity of oestrogen-related receptor α (ERRα), which has a similar tissue distribution to PGC-1α and promotes fatty acid oxidation [92,93]. An ERR inverse agonist or siRNA directed against ERRα blocked the induction of oxidative phosphorylation genes by PGC-1α [94], supporting the case for ERRα agonists, although surprisingly, mice that lack ERRα are resistant to high fat diet-induced obesity [95].

PGC-1α coactivates PPARδ, which may be an important mediator of its effects on fatty acid oxidation. Overexpression of PPARδ in skeletal muscle increased the proportion of type I fibres [96]. This manipulation or treatment of mice with selective PPARδ agonists also protected mice from diet-induced obesity [97].

A number of companies are attempting to develop PPARδ agonists, possibly incorporating activity at other PPARs to improve activity against diabetes and dyslipidaemia. Two notes of caution must be mentioned. First regulatory authorities are concerned about the potential carcinogenicity of novel PPAR agonists of all types. Second, bezafibrate is claimed to be an agonist of both PPARα and PPARδ [98], but despite being used in humans for many years, it has not been reported to have an antiobesity
effect. It is possible, however, that bezafibrate is used clinically at a dose that allows it to act as a PPARα agonist (see below, in this section) but not as a PPARδ agonist.

PGC-1α and PPARδ promote mitochondrial biogenesis in adipose tissue as well as skeletal muscle, in effect converting white into brown adipose tissue, whose main role is lipid oxidation. Overexpression of PPARδ in adipose tissue alone is sufficient to provide protection from diet-induced obesity [99]. Various other transcription factors and their coactivators and corepressors also affect mitochondrial biogenesis in skeletal muscle and adipose tissue, and may offer, or point to, targets for antiobesity drugs [100].

The enzyme glutamine fructose-6-phosphate amidotransferase (GFAT) may provide a relatively tractable target for drugs that promote mitochondrial biogenesis in skeletal muscle. It has previously been recognized that inhibitors of GFAT have potential as insulin sensitizing drugs [101] but overexpression of GFAT in liver resulted in obesity as well as insulin resistance [102,103]. GFAT regulates the rate of hexosamine synthesis. The terminal metabolite of this pathway is UDP-N-acetyl glucosamine, which glycosylates various proteins involved in nutrient sensing. Infusion of glucosamine decreased the expression of a number of mitochondrial genes involved in oxidative phosphorylation in rat skeletal muscle, and whole body energy expenditure was reduced [103]. Therefore inhibitors of GFAT might increase energy expenditure.

Activation of PPARα in liver promotes the oxidation of fatty acids [104]. PPARα knockout mice are mildly obese [105–107], and various PPARα agonists (nafenopin, MEDICA-16, GW-9578, bezafibrate) have antiobesity activity in rodents, largely, though not entirely, due to increased energy expenditure [108–111]. Some PPARα agonists, notably oleoylethanolamide, also reduce food intake [112]. Adiponectin increases the expression of PPARα, and this may contribute to its antiobesity effect in rodents [64]. However, drugs of the fibrate class are PPARα agonists, and there are no reports that they cause substantial weight loss in humans.

Inhibition of Lipid Synthesis

Paradoxically, inhibitors of fatty acid and triglyceride synthesis (figure 3) usually alter energy balance in rodents by promoting fat oxidation, though some also inhibit food intake. With the exception of ACC inhibition, the primary molecular mechanisms that link inhibition of lipid synthesis with stimulation of lipid oxidation are unclear.

**Fig. 3** Target enzymes in lipid synthesis. Acetyl-CoA is produced in the mitochondrion and condenses with oxaloacetate to form citrate. Citrate is transported out of the mitochondrion by the tricarboxylate carrier, so that fatty acid and triglyceride synthesis can take place in the cytosol. Cytosolic citrate is the starting point of the scheme. The scheme also shows that malonyl-CoA inhibits the formation of fatty acyl-carnitine, thereby preventing the entry of fatty acids into the mitochondrion for oxidation. Potential antiobesity drugs must inhibit each of the enzymes, except for AMP-activated protein kinase (AMPK), which inhibits the activity of other enzymes. SCD, stearoyl-CoA desaturase.
Fatty Acid Synthesis

(-)-Hydroxycitric acid is an example of a compound that appears to both increase fat oxidation and reduce food intake [113,114]. It is an inhibitor of ATP citrate lyase, a key enzyme of fatty acid synthesis, and is marketed as a natural supplement for weight management [115]. Like some other targets in lipid synthetic pathways, it is unclear whether peripheral (adipose tissue or liver) or hypothalamic ATP citrate lyase plays the primary role in its anorexic and thermogenic effects [116].

ACC produces malonyl-CoA. Malonyl-CoA is used to initiate fatty acid chain building by fatty acid synthase. ACC1, a cytosolic enzyme found mainly in lipogenic tissues, provides malonyl-CoA to initiate fatty acid chain building by fatty acid synthase. Malonyl-CoA produced by ACC2, an enzyme that is associated with mitochondria and found mainly in oxidative tissues, appears, by contrast, to play the role of a ‘fuel sensor’. The malonyl-CoA does this by inhibiting carnitine palmitoyl transferase 1 (CPT1), the role of which is to transfer fatty acids into the mitochondrion for oxidation. Inhibition of ACC2 promotes fatty acid oxidation by reducing the malonyl-CoA concentration and disinhibiting CPT1.

The main evidence for this concept is that ACC2 knockout mouse are lean, despite consuming more food than wild-type mice [117]. Encouragingly, the phenotype was observed in heterozygous mice, which is, arguably, a better indicator of the potential of an enzyme inhibitor. Malonyl-CoA levels were markedly reduced in heart and skeletal muscle, but not in liver, where ACC1 predominates. Nevertheless, hepatic as well as muscle fatty acid oxidation appeared to be increased, as judged by 80–90% lower hepatic lipids in the ACC2 null mouse. Adipocytes from these mice also display increased fatty acid oxidation [118].

Non-selective inhibition of ACC may also be an option. CP-610431 inhibited both ACC1 and ACC2 with IC50 values of around 50 nM and stimulated fatty option. CP-610431 inhibited both ACC1 and ACC2 also display increased fatty acid oxidation [118].

Inhibiting ACC2.) Subsequent studies have shown that C75 also promotes fat oxidation, perhaps in part due to a peripheral action [121–123], and disconnected the anorectic effect from hypothalamic fatty acid synthase inhibition [124]. Whatever, the mechanism, inhibition of fatty acid synthase seems more likely to produce toxicity than approaches that involve selective inhibition of one isozyme of an enzyme that regulates the concentration of a regulatory molecule, as in the case of ACC2.

SCD-1 is another target involved in lipid metabolism that affects energy expenditure. There are at least four isoforms of SCD-1 in mice, and two have been described in humans [125]. Mice that carry a mutant SCD-1 are resistant to obesity. Moreover, antisense oligonucleotide inhibitors of SCD-1, apparently acting in the liver, prevented diet-induced obesity in mice [126]. One suggestion is that saturated but not monounsaturated fatty acyl-CoAs potently inhibit ACC, so that knockout of SCD-1 might resemble knockout of ACC2. Other proposed mechanisms involve activation of AMP-activated protein kinase and downregulation of protein tyrosine phosphatase-1B (PTP1B) [127].

Triglyceride Synthesis

Synthesis of triglyceride (TAG) starts with esterification of glycerol-3-phosphate by fatty acyl-CoA, catalysed by GPAT. There are two forms of GPAT: one is located in the outer mitochondrial membrane (mtGPAT) and the other in the endoplasmic reticulum (erGPAT). In most tissues, mtGPAT comprises only 10% of total GPAT activity, and its role is unclear [128]. One possibility is that it diverts fatty acyl-CoA away from oxidation in the mitochondrion and sends it in the form of lysophosphatidate to the endoplasmic reticulum to be used for TAG synthesis. Thus the expression of mtGPAT mRNA is regulation by nutritional and hormonal status; its overexpression in rat primary hepatocytes both increased TAG synthesis and decreased fatty acid oxidation, and overexpression in mouse liver increased TAG synthesis, reduced fatty acid oxidation and caused marked hepatic steatosis [129]. By contrast, in mice fed on a high sucrose and fat diet, the absence of mtGPAT diverted fatty acids in liver away from TAG synthesis and towards oxidation and ketogenesis [130].

The mtGPAT knockout mouse weighs less than its wild-type counterpart and has a lower adipose tissue weight and liver fat content [128]. Energy expenditure has not been reported, although the reduction in hepatic and plasma TAG suggests that fatty acid oxidation is increased. The amount of the mitochondrial phospholipid cardiolipin...
was reduced, and it would be interesting to determine whether this affects the mitochondrial proton leak.

The last enzyme of the TAG biosynthetic pathway is acyl-CoA : diacylglycerol acyltransferase (DGAT). Two isoforms are known. DGAT1 knockout mice survive and are lean and resistant to obesity. DGAT1 knockout mice have increased energy expenditure due in part to increased physical activity but also to increased fatty acid oxidation in brown adipose and other tissues. Increased fatty acid oxidation would explain why the concentration of diacylglycerol, the substrate of DGAT, paradoxically tended to be low in white adipose tissue, skeletal muscle, and especially in liver of DGAT1 knockout mice, and not high as would be expected. Presumably the absence of DGAT1 in some other tissue promotes diacylglycerol utilization or inhibits its formation. Because the knockout mice have increased locomotor activity, this other tissue could be the brain [131,132]. White adipose tissue transplantation studies suggested that the trigger for increased energy expenditure resides in this tissue. White adipose tissue was proposed to affect energy expenditure in other tissues through an increased ratio of adiponectin to tumour necrosis factor α release, but there is little evidence to support this proposal. DGAT2 knockout mice do not survive long after birth, but studies using DGAT2 antisense suggest that inhibitors might reduce hepatic steatosis and hyperlipidaemia. In contrast to DGAT1 antisense, however, DGAT2 antisense does not have an antiobesity effect [133].

Validation of these various targets involved in lipid synthesis has mostly been from the phenotypes of genetically modified mice. In some cases, the phenotype is resistance to dietary obesity rather than leanness on a chow diet, and there are no examples where the genetic modification has been activated in an obese animal to show that pre-existing obesity can be reversed. Nevertheless, it is expected that full papers showing effects of tool compounds in vivo will soon be published for more of the targets.

Hypothalamic Targets and Their Implications for Drug Discovery

Initial interest in many of the new intracellular antiobesity targets has been driven by the phenotypes of mice in which a gene has been knocked out in the whole animal. It might seem that if the gene regulates lipid or carbohydrate metabolism, then drugs targeted towards the gene product must act peripherally. However, the hypothalamus responds to fuels of various kinds – lipids, glucose and amino acids – as well as to insulin [134], and we have suggested that resistance to obesity in the DGAT1 knockout mouse might be due to the absence of the enzyme in the brain. Resistance to obesity in the 11β-hydroxysteroid dehydrogenase-1 knockout mouse might also be due to the absence of the enzyme in the brain [135].

Consider also PTP1B. This enzyme deactivates the insulin receptor and possibly insulin receptor substrates. Inhibitors might be expected to be useful in the treatment of type 2 diabetes, but the PTP1B mouse is also resistant to obesity [136]. Because insulin promotes anabolism when it acts in the periphery, but catabolism when it acts centrally, it seems likely that the lean phenotype of the PTP1B mouse is due to the absence of the enzyme in the brain. Consistent with this view, the neuronal insulin receptor knockout mouse is obese [137], and insulin mimetics act centrally to reduce food intake [138]. Another consideration is that PTP1B also deactivates the leptin receptor and Janus-activated kinase-1, which plays a role in leptin signalling. These are also central targets. PTP1B inhibitors have not so far been shown to have antiobesity activity [136].

The existence of these central targets raises issues for drug discovery. First, the phenotypes of animals in which a gene has been knocked out globally must be interpreted with caution. Even when the gene is involved in a major pathway of fuel metabolism (e.g. fatty acid synthase), it is possible that its effects on energy balance are primarily centrally mediated. This would mean that drugs for the target would have to penetrate the brain.

Second, opposite phenotypes may result from peripheral or central actions of the drug. Inhibition of ACC2 in the periphery may be beneficial because it reduces malonyl-CoA levels. The antiobesity activity of fatty acid synthase inhibition has, by contrast, been attributed to elevation of malonyl-CoA levels in the hypothalamus [139]. Similarly, activation of AMPK in the periphery is beneficial, but in the brain activation of AMPK stimulates food intake, whilst inhibition reduces intake. There is logic in these opposing peripheral and central actions of malonyl-CoA and AMPK on energy balance. They both play a role in sensing fuel availability. In times of energy need, not only must oxidative metabolism increase but food intake must increase to replace the oxidized fuel. On the contrary, leptin, which has the role of regulating body weight, activates AMPK in the periphery to burn off fuel, whilst inhibiting AMPK in the hypothalamus to prevent the fuel being replaced [140]. (Surprisingly, intracerebroventricular infusion of insulin, which also reduces food intake, activates AMPK [141].) It may therefore be important with some drugs to avoid central penetration and with others to maximize it.
Limitations of Rodent Models

The use of rodents as models for humans presents particular issues when validating targets for thermogenic compounds. One difference is that effects of compounds are usually studied in rodents when they are growing, but we are not aware of any compound that reduced fat accretion in growing rodents but could not elicit fat loss in weight stable rodents. Other issues seem more important.

First, it can be difficult to determine whether obesity or resistance to obesity in genetically modified animals is because their energy expenditure or their energy intake differs from wild-type animals. If the genetically modified animal is obese but eats less than the wild-type animal, or is lean but eats more, then altered energy expenditure is clearly important. But what if, for example, the animal is obese and both eats more and expends more energy? In the past, some clinical researchers have interpreted such data for obese humans as evidence that obesity was due to overeating. Many animal researchers, by contrast, take fundamentally similar data divide it by body weight; find that the obese animals have a lower energy expenditure per gram body weight and come to the opposite conclusion, that is, that obesity is due to reduced energy expenditure.

Both approaches are flawed: the former fails to recognize that increased energy expenditure may be a consequence rather than a cause of obesity [14,142] and the latter that a gram of fat makes a smaller contribution to energy expenditure than a gram of lean tissue. Nor does expressing energy expenditure relative to a power of body weight (such as body weight^{0.75}) solve the problem, because such exponents were not derived to compare lean and obese animals. The best solution is to conduct an analysis of covariance of energy expenditure against body weight as discussed elsewhere [71,143]. When investigating the acute thermogenic response to a compound, variation in body composition is not an issue, but if chronic effects on energy expenditure are determined, body weight and composition may have been altered by the treatment.

A second issue is that rodents have a greater capacity for non-shivering thermogenesis than humans. They have far more brown adipose tissue than humans, and consequently more β3-adrenoceptors and UCP-1. Therefore compounds that raise sympathetic activity may affect energy balance more profoundly in rodents than humans. Moreover, targets expressed in brown adipose tissue or those that promote the conversion of white to brown adipose tissue (or mitochondrial biogenesis in white adipocytes) may be overvalued by studies in rodents.

A third issue is that humans tend to live near thermoneutrality. They wear clothes and, if necessary, they heat their buildings. Rodents are usually studied below thermoneutrality. This raises their sympathetic activity and their energy expenditure. Although this reduces the ‘window’ available for drugs to increase sympathetic activity and fat oxidation [144] and mitigates the problem of a greater thermogenic capacity in rodents, it introduces further complexity in the prediction of efficacy in humans from rodent data.

The evaluation of compounds in genetically obese rodents presents further difficulties. Rodents that have a dysfunctional leptin system, such as lep^{ob}/lep^{ob} mice and lep^{Rf1/lep^{Rf1}} rats, are very different from obese humans who have raised leptin levels. It is argued (somewhat illogically [145]) that obese humans are therefore leptin resistant, but leptin clearly has some effect in most obese humans because their obesity is far less severe than in those rare obese humans whose obesity is due to a defective leptin system [146]. The absence of a functional leptin system in some rodents results, for example, in raised hypothalamic neuropeptide Y levels, making them especially sensitive to the anorectic and, presumably, the thermogenic effects of neuropeptide Y receptor antagonists [147]. The absence of leptin also lowers sympathetic activity, though whether there is a greater or smaller response to β-adrenoceptor agonists in lep^{ob}/lep^{ob} mice may vary with background strain and age [144].

The answer would appear to be to evaluate compounds in diet-induced obese rather than genetically obese rodents. Diet-induced obesity takes time to develop, however, and there is greater body weight and fat variability than in the mutant strains. Some workers prefer to reserve diet-induced obesity for key studies.

Other types of mutant obese rodent, such as the agouti A^{v} mouse, in which the mutation is less fundamental to body weight control than leptin, or polygenic obesity, may provide results that are more predictive of efficacy in humans than lep^{ob}/lep^{ob} mice do. It may be especially interesting to conduct studies in mice that lack brown adipose tissue. Not only are they obese, but also they lack the tissue that makes thermogenic capacity in rodents so different from that in humans [148].

Conclusion

There are many possible targets for antiobesity drugs that work by stimulating energy expenditure or altering...
substrate utilization. Some of these are suggested by physiological mechanisms that are known to influence energy expenditure and may be supported by effects of compounds in rodents and humans. Others are more speculative and supported only by the phenotypes of genetically modified mice.

Ultimately, antiobesity drugs must reduce energy intake (or absorption) or increase expenditure (or excretion). Increased energy expenditure involves either increased ATP utilization or oxidation of reduced coenzymes by enzymes or pathways that are not coupled to ATP. Thermogenesis is a logical approach to the treatment of obesity, because low energy expenditure, especially low oxidation of fat, is a factor in its aetiology. Moreover, peripherally acting thermogenic drugs seem less likely to have side effects than centrally acting drugs, and those that promote fat oxidation are especially likely to have metabolic benefits. Surprisingly, knockout or inhibition of enzymes of fatty acid and triglyceride synthesis may increase energy expenditure as well as decrease intake, but in some cases this effect may be initiated centrally rather than peripherally. This caution is important if the attraction of influencing energy expenditure and substrate utilization is that the target appears to be ‘below the neck’. There is no shortage of targets. The difficulty is in deciding which, if any, is likely to deliver a drug.

Acknowledgements
We thank Mike Cawthorne for his comments on the manuscript, Julie Cakebread for typing it and John Wilding, who provided the stimulus for writing it.

References
Thermogenic and metabolic antiobesity drugs


45 Grover GJ, Mellstrom K, Ye L et al. Selective thyroid hormone receptor-β activation: a strategy for reduction of weight, cholesterol, and lipoprotein (a) with reduced cardiovascular liability. Proc Natl Acad Sci USA 2003; 100: 10067–10072.


52 Greenway FL, De Jonge L, Blanchard D, Frisard M, Smith SR. Effect of a dietary herbal supplement


92 Kamei Y, Ohizumi H, Fujitani Y et al. PPARgamma coactivator 1beta/ERR ligand 1 is an ERR protein ligand, whose expression induces a high-energy expenditure and antagonizes obesity. Proc Natl Acad Sci USA 2003; 100: 12378–12383.


94 Willy PJ, Murrar IR, Qian J et al. Regulation of PPARgamma coactivator 1a (PGC-1a) signaling by an estrogen-related receptor alpha (ERRalpha) ligand. Proc Natl Acad Sci USA 2004; 101: 8912–8917.


111 Peters JM, Aoyama T, Burns AM, Gonzalez FJ. Bezafibrate is a dual ligand for PPARx and PPARβ: studies using null mice. Biochim Biophys Acta 2003; 1632: 80–89.


142 Trevaskis JL, Butler AA. Double leptin and melanocortin-4 receptor gene mutations have an additive effect on fat mass and are associated with reduced effects of leptin on weight loss and food intake. Endocrinology 2005; 146: 4257–4265.


144 Wilson S, Arch JRS, Thurlby PL. Genetically obese C57BL/6 ob/ob mice respond normally to sympathomimetic compounds. Life Sci 1984; 35: 1301–1309.


